Cyclacel Pharma Files DEF 14A on Exec Comp & Stock Awards
Ticker: BGMSP · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 1130166
Sentiment: neutral
Topics: executive-compensation, stock-options, proxy-statement
Related Tickers: CYCC
TL;DR
Cyclacel Pharma's 2025 DEF 14A details exec stock awards for 2022-2024. See how much they're paying their top brass.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed a DEF 14A on April 24, 2025, detailing executive compensation and stock option awards for the fiscal years ending December 31, 2024, 2023, and 2022. The filing includes information on 'ReportedSCTStockOptionAwardValue' and 'YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYear' for both PEO (Principal Executive Officer) and Non-PEO members.
Why It Matters
This filing provides transparency into how Cyclacel Pharmaceuticals compensates its top executives and the value of stock awards granted, which can influence investor decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not inherently present new financial risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for executive compensation data)
- 2023-12-31 — Fiscal Year End (Reporting period for executive compensation data)
- 2022-12-31 — Fiscal Year End (Reporting period for executive compensation data)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Filer
- 200 CONNELL DRIVE (address) — Business and Mail Address
- BERKELEY HEIGHTS, NJ 07922 (address) — Business and Mail Address
- XCYTE THERAPIES INC (company) — Former Company Name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide information regarding the solicitation of proxies for the company's annual meeting of shareholders, including details on executive compensation and director nominations.
What specific compensation data is detailed for the fiscal years 2022-2024?
The filing details 'ReportedSCTStockOptionAwardValue' and 'YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYear' for both PEO and Non-PEO members for the fiscal years ending 2022, 2023, and 2024.
When was Cyclacel Pharmaceuticals, Inc. formerly known as XCYTE THERAPIES INC?
The company's name was changed from XCYTE THERAPIES INC to Cyclacel Pharmaceuticals, Inc. on December 18, 2000.
What is the business address of Cyclacel Pharmaceuticals, Inc.?
The business address is 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ 07922.
What is the Standard Industrial Classification (SIC) code for Cyclacel Pharmaceuticals, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).